Literature DB >> 15681468

Food and Drug Administration regulation of in vitro diagnostic devices.

Elizabeth Mansfield1, Timothy J O'Leary, Steven I Gutman.   

Abstract

The Food and Drug Administration regulates the sale and distribution of laboratory devices under a statutory and regulatory framework that is unfamiliar to most clinical laboratory scientists. In this article we briefly describe the criteria that are used to classify and review in vitro diagnostic devices. We discuss the similarities and differences between devices that are not subject to premarket review, and those that are required to undergo either a premarket application or premarket notification [510(k)] pathway. We then discuss the methods that the Food and Drug Administration uses to assess the performance of in vitro diagnostic devices in the marketplace as a component of the total life cycle approach to medical device regulation.

Mesh:

Year:  2005        PMID: 15681468      PMCID: PMC1876654          DOI: 10.1016/S1525-1578(10)60002-5

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  10 in total

1.  Bringing diagnostic technologies to the clinical laboratory: Rigor, regulation, and reality.

Authors:  Gordon Whiteley
Journal:  Proteomics Clin Appl       Date:  2008       Impact factor: 3.494

2.  HIV testing updates and challenges: when regulatory caution and public health imperatives collide.

Authors:  Bernard M Branson
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

3.  Microfluidics in Malignant Glioma Research and Precision Medicine.

Authors:  Meghan Logun; Wujun Zhao; Leidong Mao; Lohitash Karumbaiah
Journal:  Adv Biosyst       Date:  2018-04-02

Review 4.  Role of biomarkers of nephrotoxic acute kidney injury in deliberate poisoning and envenomation in less developed countries.

Authors:  Fahim Mohamed; Zoltan H Endre; Nicholas A Buckley
Journal:  Br J Clin Pharmacol       Date:  2015-05-28       Impact factor: 4.335

Review 5.  The path to clinical proteomics research: integration of proteomics, genomics, clinical laboratory and regulatory science.

Authors:  Emily S Boja; Henry Rodriguez
Journal:  Korean J Lab Med       Date:  2011-04

Review 6.  A research agenda for helminth diseases of humans: diagnostics for control and elimination programmes.

Authors:  James S McCarthy; Sara Lustigman; Guo-Jing Yang; Rashida M Barakat; Héctor H García; Banchob Sripa; Arve Lee Willingham; Roger K Prichard; María-Gloria Basáñez
Journal:  PLoS Negl Trop Dis       Date:  2012-04-24

Review 7.  Navigating the rapids: the development of regulated next-generation sequencing-based clinical trial assays and companion diagnostics.

Authors:  Saumya Pant; Russell Weiner; Matthew J Marton
Journal:  Front Oncol       Date:  2014-04-17       Impact factor: 6.244

8.  Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer.

Authors:  Shakun M Malik; Richard Pazdur; Jeffrey S Abrams; Mark A Socinski; William T Sause; David H Harpole; John J Welch; Edward L Korn; Claudio Dansky Ullmann; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2014-10       Impact factor: 15.609

9.  FDA perspectives on potential microarray-based clinical diagnostics.

Authors:  Zivana Tezak; Daya Ranamukhaarachchi; Estelle Russek-Cohen; Steven I Gutman
Journal:  Hum Genomics       Date:  2006-01       Impact factor: 4.639

Review 10.  Analytical validation considerations of multiplex mass-spectrometry-based proteomic platforms for measuring protein biomarkers.

Authors:  Emily S Boja; Thomas E Fehniger; Mark S Baker; György Marko-Varga; Henry Rodriguez
Journal:  J Proteome Res       Date:  2014-11-18       Impact factor: 4.466

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.